Q4 Results: Mankind Pharma Rallies 3% After Profit Jumps 30% On Strong Chronic Therapy Demand

Mumbai, May 20:Shares of Mankind Pharma surged on Wednesday after the drugmaker reported a strong set of March-quarter earnings, driven by robust growth in its domestic formulations business, rising demand for chronic therapies and improving operational margins.

The stock gained over three per cent at Rs 2,570 as investors cheered the company’s better-than-expected earnings performance and upbeat outlook for its speciality and consumer healthcare segments.

Mankind Pharma reported a consolidated net profit of ₹554 crore for the quarter ended March 31, marking a 30% year-on-year increase from ₹425 crore a year earlier. Revenue from operations rose nearly 12% to ₹3,443 crore, supported by healthy growth across prescription medicines and consumer healthcare products.

Chronic Therapies Drive Growth

Investors cheered the stock as results exceeded expectations. Source: NSE

Investor sentiment was boosted by strong traction in chronic therapy segments such as cardiac, anti-diabetic and gastrointestinal treatments, which continued to outperform the broader pharmaceutical market.

The company’s domestic formulations business remained the key growth driver during the quarter, aided by higher prescriptions, improved field execution and increasing penetration in speciality therapies.

Mankind’s chronic portfolio is witnessing sustained momentum as the company gradually shifts focus towards higher-margin therapies and premium products.

The company also continued to see steady demand for its consumer healthcare products, including over-the-counter medicines and wellness brands, which contributed positively to revenue growth.

Margins Improve Sharply

Operational performance improved significantly during the quarter. Mankind Pharma reported an adjusted EBITDA margin of 27.1%, an expansion of nearly 400 basis points from the year-ago period.

The improvement was driven by better product mix, operating leverage and cost optimisation measures. Higher contribution from chronic therapies and speciality products also helped support margins.

The company’s profitability remained ahead of expectations despite a challenging macroeconomic environment and rising competitive intensity in the domestic pharmaceutical market.

Bharat Serums Integration Aids Performance

The company said performance was also supported by improving traction in the business acquired from Bharat Serums and Vaccines, which Mankind Pharma bought to strengthen its speciality portfolio.

Management indicated that integration-related issues have started easing, while demand for speciality products in women’s healthcare and critical care continues to improve.

For the full FY26 financial year, the company reported revenue of around ₹14,278 crore, up 17% year-on-year.

Defensive Buying Supports Pharma Stocks

The rally in Mankind Pharma also came amid broader strength in pharmaceutical stocks, as investors increasingly shifted toward defensive sectors during a period of rising global uncertainty, elevated crude oil prices and inflation concerns.

The company remains well-positioned to benefit from rising healthcare spending, strong domestic demand and continued expansion into high-growth chronic and speciality therapy segments.

Source:

• https://www.nseindia.com/get-quote/equity/MANKIND/Mankind-Pharma-Limited